Je dividenda Integrated Biopharma bezpečná?
Integrated Biopharma zvyšuje dividendu už 0 rokov.
V priebehu posledných 10 rokov Integrated Biopharma ročne 0 % znížené.
Na 5-ročnú perspektívu klesol výplata o 0 %.
Analytici očakávajú pre bežný obchodný rok nárast o Zníženie dividendy vo výške -100,000%.
Integrated Biopharma Aktienanalyse
Čo robí Integrated Biopharma?
Integrated Biopharma Inc. is a New York-based company specializing in the development, manufacturing, and marketing of health products. Founded in 1979, the company has acquired extensive experience in the industry.
Integrated Biopharma's business activities encompass four main areas: biopharmaceuticals, pharmaceuticals, dietary supplements, and veterinary products. Each of these divisions is focused on the development and manufacturing of specific products, contributing to the overall business of the company.
In the biopharmaceuticals sector, the company focuses on developing therapeutic products for rare and severe diseases. The product development is carried out in close collaboration with the Columbia University Medical School.
In the pharmaceuticals sector, Integrated Biopharma produces generics as well as its own products targeting the treatment of diabetes, cancer, and cardiovascular diseases, among others.
Dietary supplements are also part of Integrated Biopharma's product portfolio, with a focus on manufacturing vitamin and mineral supplements, as well as herbal dietary supplements.
Additionally, the company offers a variety of veterinary products, including preparations for the health of domestic and farm animals, as well as medications for the treatment of animal diseases.
One important business model of Integrated Biopharma is the manufacturing and marketing of mostly patent-free, yet high-quality products. Furthermore, the company collaborates closely with other companies and institutions to develop new products and technologies.
Another important strategy of Integrated Biopharma is to market its products worldwide. The company has distribution partners in many countries, including China, Canada, Mexico, France, and Germany.
Integrated Biopharma places a strong emphasis on the highest quality standards and therefore invests in modern infrastructure and a well-trained workforce. The company operates its own production facilities and research institutions in the USA and China.
Among Integrated Biopharma's most well-known products are the diabetes medication "GlipiZIDE," the carcinoma medication "Paclitaxel," and the veterinary antibiotic "Gentamicin Sulfate."
Overall, Integrated Biopharma has received numerous awards and certifications for its products and business activities in recent years. The high quality and effectiveness of its preparations, as well as its responsible approach to resources and the environment, make Integrated Biopharma an important player in the healthcare industry. Integrated Biopharma je jednou z najobľúbenejších spoločností na Eulerpool.com.Investičné plány do akcií ponúkajú atraktívnu možnosť pre investorov na dlhodobú výstavbu majetku. Jednou z hlavných výhod je tzv. Cost-Average-Effekt: Pravidelnou investíciou pevnej sumy do akcií alebo do akciových fondov automaticky kupujete viac podielov, keď sú ceny nízke, a menej, keď sú vysoké. To môže viesť k výhodnejšej priemernej cene za podiel v priebehu času. Okrem toho investičné plány do akcií umožňujú aj malým investorom prístup k drahým akciám, keďže sa dá investovať už s malými sumami. Pravidelná investícia tiež podporuje disciplinovanú investičnú stratégiu a pomáha predchádzať emocionálnym rozhodnutiam, ako je impulzívne kupovanie alebo predávanie. Ďalej investorom prináša potenciálny nárast hodnoty akcií, ako aj výplaty dividend, ktoré môžu byť reinvestované, čo zvyšuje efekt zloženého úroku a tým rast investovaného kapitálu.